Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bortezomib: a new pro-apoptotic agent in cancer treatment.
Russo A, Bronte G, Fulfaro F, Cicero G, Adamo V, Gebbia N, Rizzo S. Russo A, et al. Among authors: fulfaro f. Curr Cancer Drug Targets. 2010 Feb;10(1):55-67. doi: 10.2174/156800910790980250. Curr Cancer Drug Targets. 2010. PMID: 20088794
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer.
Correale P, Fulfaro F, Marsili S, Cicero G, Bajardi E, Intrivici C, Vuolo G, Carli AF, Caraglia M, Del Prete S, Greco E, Gebbia N, Francini G. Correale P, et al. Among authors: fulfaro f. Cancer Chemother Pharmacol. 2005 Dec;56(6):563-8. doi: 10.1007/s00280-005-1024-1. Epub 2005 Jul 23. Cancer Chemother Pharmacol. 2005. PMID: 16041610 Clinical Trial.
Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome.
Vincenzi B, Santini D, Galluzzo S, Russo A, Fulfaro F, Silletta M, Battistoni F, Rocci L, Zobel BB, Adamo V, Dicuonzo G, Tonini G. Vincenzi B, et al. Among authors: fulfaro f. Clin Cancer Res. 2008 Jul 1;14(13):4219-24. doi: 10.1158/1078-0432.CCR-08-0077. Clin Cancer Res. 2008. PMID: 18594003 Free article.
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma.
Valerio MR, Tagliaferri P, Raspagliesi F, Fulfaro F, Badalamenti G, Arcara C, Cicero G, Russo A, Venuta S, Guarneri G, Gebbia N. Valerio MR, et al. Among authors: fulfaro f. Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:79-85. doi: 10.1111/j.1525-1438.2006.00324.x. Int J Gynecol Cancer. 2006. PMID: 16515572 Clinical Trial.
88 results